ALKS
Alkermes plc
ALKS's outlook is improving, though it still trails on the overall score.
LLY
Eli Lilly and Company
LLY has the edge over ALKS overall, supported by stronger fundamentals and stronger modeled upside.
ALKS Fundamentals
| Metric | Status |
|---|---|
| Healthy | |
| Under pressure | |
| Stable | |
| Weak |
ALKS's revenue is currently healthy, and its cash flow is stable, but its profitability and balance sheet are under pressure.
LLY Fundamentals
| Metric | Status |
|---|---|
| Healthy | |
| Strong | |
| Strong | |
| Healthy |
LLY's revenue, profitability, cash flow and balance sheet are all currently healthy.
ALKS PE Valuation
ALKS has no meaningful PE right now: it lost money over the past year.
LLY PE Valuation
| Level | PE | Price | Vs current |
|---|---|---|---|
| Cheap | 27x | $845 | -41% |
| Forward | 30x | $1,427 | — |
| Current | 46x | $1,427 | — |
| Fair | 48x | $1,466 | +2.7% |
| Expensive | 85x | $2,612 | +83% |
Historical ranges are pointers, not guarantees.
LLY's PE is in its fair range at 46x. If earnings grow as analysts expect, today's price would be 30x next year's earnings, in its cheap range.
ALKS Forward outlook
| Metric | Outlook |
|---|---|
| -- | |
| Losses shrinking | |
| Growth | |
| Stable | |
| Limited | |
| Low |
Analysts expect ALKS's losses to shrink, with revenue growing. However, they disagree widely on these estimates.
LLY Forward outlook
| Metric | Outlook |
|---|---|
| Strongly improving | |
| Strong growth | |
| Strong growth | |
| Strongly improving | |
| Limited | |
| Moderate |
LLY has the edge over ALKS on the outlook, with more favorable profitability expectations.
ALKS Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Q3 2026 | -$0.02 | -101% |
| Q2 2026 | $0.38 | -82% |
| Q1 2026 | $0.90 | -57% |
| Q4 2025 | $1.43 | -34% |
| Q3 2025 | $2.02 | +2% |
| Q2 2025 | $2.08 | +22% |
| Q1 2025 | $2.09 | -18% |
| Q4 2024 | $2.17 | +3.3% |
ALKS has swung to a loss: it lost $0.02 per share over the past year, after a profit the year before.
LLY Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Forward | $46.83 | +52% |
| Q3 2026 | $30.81 | +51% |
| Q2 2026 | $29.80 | +95% |
| Q1 2026 | $28.15 | +129% |
| Q4 2025 | $22.95 | +96% |
| Q3 2025 | $20.44 | +121% |
| Q2 2025 | $15.30 | +88% |
| Q1 2025 | $12.29 | +81% |
| Q4 2024 | $11.71 | +102% |
LLY has the edge over ALKS on earnings quality, reporting a profit while its opponent remains loss making.
ALKS Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q3 2026 | $480.1M | +22% |
| Q2 2026 | $496M | +27% |
| Q1 2026 | $392.9M | +28% |
| Q4 2025 | $384.5M | -11% |
| Q3 2025 | $394.2M | +4.2% |
| Q2 2025 | $390.7M | -2.1% |
| Q1 2025 | $306.5M | -13% |
| Q4 2024 | $430M | +14% |
ALKS's revenue is recovering but still below its 2023 peak: $480M last quarter, up 22% from the same quarter a year ago.
| Quarter | Margin | YoY |
|---|---|---|
| Q3 2026 | 7.5% | -15 points |
| Q2 2026 | 3.7% | -20 points |
| Q1 2026 | -12% | -17 points |
| Q4 2025 | 15% | -23 points |
| Q3 2025 | 23% | -5.1 points |
| Q2 2025 | 24% | -3.7 points |
| Q1 2025 | 4.5% | -7.9 points |
| Q4 2024 | 38% | -9.5 points |
ALKS's operating margin was 7.5% last quarter, down 15 points from the same quarter a year ago.
LLY Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q3 2026 | $24.4B | +39% |
| Q2 2026 | $23B | +48% |
| Q1 2026 | $19.8B | +56% |
| Q4 2025 | $19.3B | +43% |
| Q3 2025 | $17.6B | +54% |
| Q2 2025 | $15.6B | +38% |
| Q1 2025 | $12.7B | +45% |
| Q4 2024 | $13.5B | +45% |
LLY has the edge over ALKS on sales, with more consistent year-over-year improvement.
| Quarter | Margin | YoY |
|---|---|---|
| Q3 2026 | 34% | -6.6 points |
| Q2 2026 | 40% | -3.3 points |
| Q1 2026 | 45% | +18 points |
| Q4 2025 | 43% | +5.6 points |
| Q3 2025 | 41% | +27 points |
| Q2 2025 | 44% | +12 points |
| Q1 2025 | 27% | -1.8 points |
| Q4 2024 | 37% | +10 points |
LLY has the edge over ALKS on profitability, with a higher operating margin.
ALKS Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q3 2026 | $90.1M | +6.8% |
| Q2 2026 | $137M | -0.1% |
| Q1 2026 | -$169.8M | -291% |
| Q4 2025 | $170.1M | -5.8% |
| Q3 2025 | $84.4M | +15% |
| Q2 2025 | $137.2M | -1.2% |
| Q1 2025 | $88.7M | +595% |
| Q4 2024 | $180.6M | +100% |
ALKS still generates free cash flow, though less than at its 2023 peak: $227M over the past year.
LLY Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q3 2026 | $8.2B | +22% |
| Q2 2026 | $7.8B | +458% |
| Q1 2026 | $3B | +1826% |
| Q4 2025 | $677.9M | -31% |
| Q3 2025 | $6.7B | +186% |
| Q2 2025 | $1.4B | +476% |
| Q1 2025 | $156.1M | -13% |
| Q4 2024 | $977.8M | +$2.4B |
LLY has the edge over ALKS on cash flow, with more consistent year-over-year improvement.
ALKS Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | +1.7% | +2.9M shares |
| 1 year | +4.7% | +7.9M shares |
| 3 years | +2.6% | +4.5M shares |
| 5 years | +9.2% | +14.9M shares |
| Available history | +12% | +19.3M shares |
ALKS has 176M diluted shares, up 4.7% from a year ago.
| Quarter | Spent |
|---|---|
| Q3 2026 | — |
| Q2 2026 | — |
| Q1 2026 | $27.7M |
| Q4 2024 | $1,000 |
| Q3 2024 | $115.6M |
LLY Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | 0% | -300K shares |
| 1 year | -0.6% | -5.4M shares |
| 3 years | -0.7% | -6.4M shares |
| 5 years | -1.9% | -17.4M shares |
| Available history | -4.5% | -42.3M shares |
LLY has the edge over ALKS on shareholder dilution, with a more favorable share count trend.
| Quarter | Spent |
|---|---|
| Q3 2026 | $377M |
| Q2 2026 | $1.6B |
| Q1 2026 | $2.4B |
| Q4 2025 | $1.5B |
| Q3 2025 | $708.1M |
| Q2 2025 | $692.2M |
| Q1 2025 | $1.2B |
| Q4 2024 | $2.1B |
LLY spent $5.8B buying back its own shares over the past year, up 26% from the year before.
ALKS Net Leverage
| Quarter | Net Leverage | Status |
|---|---|---|
| Q3 2026 | 6.0x | High |
| Q2 2026 | 5.5x | High |
| Q1 2026 | 5.0x | High |
| Q4 2025 | -1.4x | Net Cash |
| Q3 2025 | -1.6x | Net Cash |
| Q2 2025 | -1.3x | Net Cash |
| Q1 2025 | -1.0x | Net Cash |
| Q3 2024 | -0.2x | Net Cash |
ALKS's net debt is about 6.0 years of its operating earnings (EBITDA), after holding more cash than debt a year ago.
LLY Net Leverage
| Quarter | Net Leverage | Status |
|---|---|---|
| Q3 2026 | 1.2x | Healthy |
| Q2 2026 | 1.3x | Healthy |
| Q1 2026 | 1.2x | Healthy |
| Q4 2025 | 1.3x | Healthy |
| Q3 2025 | 1.3x | Healthy |
| Q2 2025 | 2.0x | Healthy |
| Q1 2025 | 2.3x | Moderate |
| Q4 2024 | 2.1x | Moderate |
LLY has the edge over ALKS on leverage, with a lower net debt burden relative to earnings.
ALKS Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 58.9 | Neutral |
| Stochastic | 53.5 | Neutral |
ALKS's weekly RSI is 59 (neutral) and its Stochastic is 53 (neutral).
LLY Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 68.3 | Neutral |
| Stochastic | 84.1 | Overbought |
LLY's weekly RSI is 68 (neutral) and its Stochastic is 84 (overbought).
ALKS PE vs Healthcare Sector
| Metric | ALKS | Sector median | Relative |
|---|---|---|---|
| PE | 119x | 26x | 362% above |
| PE % | 96 | 29 | 67 pts above |
ALKS has no meaningful PE right now: it lost money over the past year.
LLY PE vs Healthcare Sector
| Metric | LLY | Sector median | Relative |
|---|---|---|---|
| PE | 46x | 26x | 79% above |
| PE % | 48 | 29 | 19 pts above |
LLY has the edge over ALKS on valuation relative to its sector.
ALKS Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $43.3 | 8.5% above |
| 20 week MA | $46.8 | 0.3% above |
| 50 week MA | $39.2 | 20% above |
| 100 week MA | $34.7 | 35% above |
| 200 week MA | $31.2 | 51% above |
ALKS is in an uptrend: it's above all five of its weekly moving averages, and 51% above its 200-week average.
LLY Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $1,279.4 | 12% above |
| 20 week MA | $1,218.8 | 17% above |
| 50 week MA | $1,102.2 | 29% above |
| 100 week MA | $954.1 | 50% above |
| 200 week MA | $797.5 | 79% above |
LLY is in an uptrend: it's above all five of its weekly moving averages, and 79% above its 200-week average.
ALKS Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2020 | $20.4 | $21.5 | +5% |
| 2021 | $21.5 | $24.1 | +12% |
| 2022 | $24.1 | $25.5 | +5.8% |
| 2023 | $25.5 | $27.7 | +8.8% |
| 2024 | $27.7 | $29.6 | +6.5% |
| 2025 | $29.6 | $28.5 | -3.6% |
| 2026 YTD | $28.5 | $47.0 | +65% |
ALKS has the edge over LLY on returns for 2026, with the stronger performance.
LLY Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2020 | $131.5 | $166.7 | +27% |
| 2021 | $166.7 | $273.1 | +64% |
| 2022 | $273.1 | $367.9 | +35% |
| 2023 | $367.9 | $582.9 | +58% |
| 2024 | $582.9 | $783.2 | +34% |
| 2025 | $783.2 | $1,077.8 | +38% |
| 2026 YTD | $1,077.8 | $1,427.3 | +32% |
LLY has finished every year since 2020 higher, and it's up 32% so far in 2026.